News Bristol-Myers Squibb Company Sao Paulo

Equities

BMYB34

BRBMYBBDR000

Market Closed - Sao Paulo Other stock markets 12:28:55 28/06/2024 am IST			5-day change	1st Jan Change
229 ^BRL	-2.35%		+4.21%	-8.36%

27/06	Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	MT
26/06	2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	27/06	MT
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	27/06	MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	26/06	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06	MT
European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab	24/06	AQ
Bristol Myers: accelerated approval in colorectal cancer	24/06	CF
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)	22/06	BU
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	22/06	CI
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval	22/06	MT
US FDA approves Bristol Myers' colorectal cancer therapy	21/06	RE
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo	21/06	MT
Bristol Myers: application validated for subcutaneous Opdivo	21/06	CF
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab	21/06	BU
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo	21/06	CI
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024	20/06	BU
Bristol Myers: ex-CEO of Agilent joins Board of Directors	19/06	CF
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors	19/06	BU
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024	19/06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 11:36 pm IST